The effects and risks of the use of intravenous thrombolysis between 4.5 and 24 hours after the onset of a posterior circulation ischemic stroke are not well studied.

Intravenous thrombolysis with alteplase is the only approved treatment for acute ischemic stroke, but its efficacy and safety when administered more than 3 hours after the onset of symptoms have no ...

Our study revealed a significant increase in blood-flow rates after administration of either urokinase or alteplase; however, significantly more patients treated with alteplase achieved goal blood ...

Alteplase activity adequate to lyse a clot in the venous-access device was maintained throughout the study. Although alteplase activity levels did fall to below the commonly accepted threshold for ...

Cardiology > Strokes Alteplase Not Harmful in NOAC Users, Even in a More Bleeding-Prone Cohort — No excess brain bleeds in an Asian population receiving lytic therapy for stroke by Nicole Lou ...

Patients with minor nondisabling acute ischemic stroke who were treated with alteplase vs. aspirin did not experience an increased likelihood of favorable functional outcome after 90 days ...

When administered within 4 to 5 hours of stroke onset, the thrombolytic drug alteplase significantly increased the likelihood of a positive outcome, researchers reported in The Lancet.Although ...

Boehringer Ingelheim (BI) is celebrating after an independent evaluation in the UK has reconfirmed that the benefits of its clot-busting drug alteplase outweigh the risks for acute ischaemic stroke.

For patients with ischemic stroke, tenecteplase seems to be a reasonable alternative to alteplase in terms of effectiveness and safety outcomes.

Findings seen in patients with posterior circulation stroke and with no planned thrombectomy who received alteplase 4.5 to 24 hours after stroke onset.

The stroke drug alteplase is safe and effective between three and 4.5 hours post-stroke, as well as within the conventional three-hour treatment window. This is the conclusion of authors of an ...

When treating patients with acute ischemic stroke within 4.5 hours of symptom onset, tenecteplase provides noninferior outcomes compared with alteplase (Activase; Genentech), with similar safety, ...